Abstract: [Problem] To prevent either of two packet data having the same content from being affected by noise [Solution] A packet data transmission device (not shown) transmits first packet data 1A, . . . and second packet data 1B, . . . having the same content intermittently with an idle time I therebetween. When the length of the first and second packet data 1A, . . . , 1B, . . . is denoted by LP, the length of the idle time I is denoted by LI, the duration of low-frequency noise N is denoted by LN, the time with no low-frequency noise from the occurrence of one low-frequency noise N to the occurrence of the next low-frequency noise N is denoted by LC, the following expressions (1), (2) are satisfied. Consequently, either the first packet data or the second packet data is transmitted to a receiver without being affected by noise.

Abstract: To provide a novel method for suppressing rejection after corneal transplantation. The method for suppressing rejection after corneal transplantation includes administering an effective amount of a Rho kinase inhibitor to a patient who needs it.

Abstract: An image processing device comprises an enhancement processing unit that enhances a speckle pattern in an ocular fundus tomographic image. A region-of-interest setting unit sets a desired region in the ocular fundus tomographic image with the enhanced speckle pattern as a region-of-interest, and a feature value extracting unit extracts a feature value of the speckle pattern in the region-of-interest. A disease determining unit makes disease determination for an ocular fundus on the basis of the feature value, and a mapping unit maps, in the ocular fundus tomographic image, a site of the ocular fundus that is determined to have a disease.

Abstract: A technique is provided for reducing the discoloration of an aqueous composition containing a halogenated isoquinoline derivative during high-temperature preservation. An aqueous composition comprising a compound represented by Formula (1): wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a prostaglandin.

Abstract: The present invention pertains to a drug available for long-term continuous administration for preventing or treating glaucoma or ocular hypertension, said drug showing no decrease in efficacy during long-term administration and exhibiting a stable ocular hypotensive effect. The present invention pertains to a therapeutic agent for glaucoma or ocular hypertension that is to be continuously administered for a long period of time, said drug comprising an Rho kinase inhibitor, more specifically, to a therapeutic agent comprising an Rho kinase inhibitor for treating glaucoma or ocular hypertension in a patient suffering from glaucoma or ocular hypertension who has been administered with a therapeutic agent comprising the Rho kinase inhibitor for treating glaucoma or ocular hypertension continuously over a definite period of time and needs a further enhanced ocular hypotensive effect.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of primary biliary cirrhosis (PBC), in which containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof.

Abstract: In the present invention, an edge face of an diaphragm ring (4) has a part (a locked portion) wherein a plurality of depressions (62) are formed and a substantially flat surface wherein no depression (62) is formed, and by a simple operation of operating a link releaser (52) so as to rotate the diaphragm ring (4), it is possible to switch between a click mode and a non-click mode. When taking still images, a diaphragm value can be fixed by using the click mode, and when video is taken, the diaphragm value can be smoothly changed during imaging by using the non-click mode.

Abstract: The present invention provides a novel corneal thickness modulating agent. The present invention pertains to a corneal thickness modulating agent containing 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof or a solvate thereof.

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

Abstract: The tomographic image capturing device of the present invention comprises a display means (18) configured to: split light from a light source (11) into measurement light and reference light and cause the measurement light and the reference light to be incident to an object (E) and a reference object (49), respectively; capture tomographic images of the object (E) on the basis of interference light generated by superposition of the measurement light reflected from the object (E) and the reference light reflected from the reference object (49); and display tomographic pictures of the object generated on the basis of the captured tomographic images. The tomographic image capturing device has a first image capturing mode and a second image capturing mode. The first image capturing mode is a mode in which the measurement light is two-dimensionally scanned by raster scan to be incident to the object (E) and the tomographic images of the object (E) are captured.

Abstract: This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methyl sulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl} acetic acid, a salt thereof, or a solvate of either.

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor (1).

Abstract: [Problem] To allow imaging light to be appropriately received by a second camera in the case where a first imaging mode (color imaging mode) is changed to a second imaging mode (autofluorescence imaging mode). [Solution] In the first imaging mode, using a dichroic mirror 30 allows light LB to be received by both a first camera C1 and a second camera C2. In the second imaging mode, using a transparent glass 31 allows light LB to be received by the second camera C2. With this configuration, both in the first imaging mode and in the second imaging mode, light LB from an ocular fundus is appropriately received by the second camera C2 whereby an appropriate ocular fundus image can be taken.

Abstract: The intraocular lens insertion tool includes a nozzle main body having a nozzle portion 15, a stage portion capable of disposing the intraocular lens 2 in the nozzle main body, and a plunger 60 that presses the intraocular lens 2 set in the stage portion by a leading end, thereby releasing the intraocular lens 2 into an eyeball. The leading end portion 10a of the nozzle portion 15 is obliquely cut so that, as it goes to the front side from the optical axis rear side of intraocular lens 2, the position of the end surface is located on the front side, and at the leading end 61d of the plunger 60, a protruding portion 61e is provided which protrudes to the front side so as to be able to place the surface of the optical axis rear side of the intraocular lens 2.

Abstract: A technique is provided for reducing the discoloration of an aqueous composition containing a halogenated isoquinoline derivative during high-temperature preservation. An aqueous composition comprising a compound represented by Formula (1): wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a ? blocker.

Abstract: A technique is provided for reducing the discoloration of an aqueous composition containing a halogenated isoquinoline derivative during high-temperature preservation. An aqueous composition comprising a compound represented by Formula (1): wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a prostaglandin.

Abstract: A pharmacotherapy is provided for preventing glaucoma or preventing or treating ocular hypertension, the pharmacotherapy providing potent intraocular pressure-lowering action with fast-acting properties and prolonged duration. A combination of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and an ?2 agonist for preventing or treating glaucoma.

Abstract: A technique is provided for suppressing the crystal precipitation of an aqueous composition containing a halogenated isoquinoline derivative during low-temperature preservation. An aqueous composition comprising a compound represented by Formula (1): wherein x represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and brimonidine or a salt thereof.